English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

ß₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy.

MPS-Authors
/persons/resource/persons219342

Krause,  Maximilian
Max Planck Institute of Molecular Cell Biology and Genetics, Max Planck Society;

/persons/resource/persons219669

Shevchenko,  Anna
Max Planck Institute of Molecular Cell Biology and Genetics, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Eke, I., Deuse, Y., Hehlgans, S., Gurtner, K., Krause, M., Baumann, M., et al. (2012). ß₁Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. The Journal of Clinical Investigation, 122(4), 1529-1540.


Cite as: https://hdl.handle.net/21.11116/0000-0001-08B0-F
Abstract
Integrin signaling critically contributes to the progression, growth, and therapy resistance of malignant tumors. Here, we show that targeting of β? integrins with inhibitory antibodies enhances the sensitivity to ionizing radiation and delays the growth of human head and neck squamous cell carcinoma cell lines in 3D cell culture and in xenografted mice. Mechanistically, dephosphorylation of focal adhesion kinase (FAK) upon inhibition of β? integrin resulted in dissociation of a FAK/cortactin protein complex. This, in turn, downregulated JNK signaling and induced cell rounding, leading to radiosensitization. Thus, these findings suggest that robust and selective pharmacological targeting of β? integrins may provide therapeutic benefit to overcome tumor cell resistance to radiotherapy.